E-mail us

Meet Crystal Pharmatech at MIDD+ Boston 2024

Join Crystal Pharmatech Subject Matter Expert, Ridwan Islam, M. Pharm., Ph.D., at MIDD+ Boston, hosted by Simulations Plus, Inc. on May 6-7.

Register for scientific presentations and hands-on learning at: https://lnkd.in/eUefupXz

Utility of PBPK Modeling as Step 1 in a 3-Step First Time Right Crystal Pharmatech Formulation

PBPK modelling is a valuable tool to address a much wider range of pharmaceutical applications besides drug-drug interactions. We present here PBPK modeling applications routinely used at our CDMO for in-vitro to in-vivo translation and pharmacokinetic modelling in preclinical species in addition to first-in-human pharmacokinetic predictions.

Linking of in-silico quantitative structure–property relationship models with (PBPK) modelling is Step 1 of a tailored Formulation for Phase I. Combined with parameter sensitivity we can clearly identify the key compound API Form and Formulation properties.

This leads to the fastest, most efficient formulation development with visibility into future clinical trials.

Related CRO & CDMO Services

Related Updates in Crystal Pharmatech

Contact Us
bd_global@crystalpharmatech.com +1-609-604-8303
Suite 500-B, 3000 Eastpark Blvd, Cranbury, New Jersey 08512, USA
6800 Kitimat Rd, Unit 1, Mississauga, Ontario, Canada L5N 5M1
Suite B4-101, Biobay, 218 Xinghu Street, Suzhou Industrial Park, Suzhou, China, 215123
Suite 500-B, 3000 Eastpark Blvd, Cranbury, New Jersey 08512, USA
bd_global@crystalpharmatech.com +1-609-604-8303